Efficacy and Safety of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients: Real-World Data

Introduction: Glecaprevir/pibrentasvir (G/P) is a pan-genotypic direct-acting antiviral therapy approved for use in adults with chronic hepatitis C virus (HCV) infection.This study aimed to assess the real-world efficacy and safety profile of G/P in individuals with chronic HCV.Materials and Methods: The analysis included patients over 18 years with detectable HCV-RNA who began G/P treatment for chronic HCV between January 1, 2021, and March 1, 2024.The primary outcome measure was sustained virologic response (SVR), defined as undetectable HCV-RNA 12 weeks after therapy completion.Safety and tolerability of the regimen were also evaluated.Results: G/P was administered to 191 patients, of whom 85.5% were male.Among them, 124 patients (64.9%) reported intravenous drug use.The most frequently identified genotype was GT 3 (57.1%).At 12 weeks post-treatment, 105 patients returned for follow-up, and all achieved SVR12.Adverse events occurred in 12 patients (6.3%).One patient discontinued treatment at week 4 due to pruritus and rash.Conclusion: G/P demonstrates high effectiveness, good tolerability, and a favorable safety profile as a pan-genotypic therapeutic option for chronic HCV infection.